BOK Financial’s Intellia Therapeutics NTLA Stock Holding History

BOK Financial’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-161	Closed	-$2.84K	–	1409
2024 Q3	$2.84K	Buy	+161	New	+$3.71K	﹤0.01%	1122

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BOK Financial's NTLA Position: Q4 2024 in Review

BOK Financial sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 161 shares — an estimated $2.84K sold.

BOK Financial first reported a position in NTLA in Q3 2024 and held it in 1 quarter. The position peaked at $2.84K in Q3 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

BOK Financial reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
BOK Financial sold 161 Intellia Therapeutics shares in Q4 2024, an estimated $2.84K.
BOK Financial first reported a position in Intellia Therapeutics in Q3 2024 and held it in 1 quarter.
BOK Financial's Intellia Therapeutics position peaked at $2.84K in Q3 2024.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on BOK Financial's 13F filing for Q4 2024, filed 14 Feb 2025.